Michael Helsel
- Role
- m & a Shareholder at Greenberg Traurig, LLP
- Location
- New York, NY, US
- LinkedIn followers
- 500 followers
About Michael Helsel
Michael D. Helsel is an M&A shareholder in the Corporate & Securities Practice of the…
Experience
m & a Shareholder
Feb 2005 — Present
Interprivate II Acquisition Corp. in its $1.2 billion business combination with Getaround (closing pending) Memic Innovative Surgery Ltd, a private Israeli company, in connection with the execution of a definitive business combination agreement with MedTech Acquisition Corporation, a publicly traded special purpose acquisition company, at a pro forma equity value of approximately $1 billion (definitive agreement terminated) SH Parent, Inc.(Parallel), one of the largest privately-held multi-state cannabis operators in the U.S, in its definitive agreement to combine with Ceres Acquisition Corp. and its anticipated NEO listing and enterprise value of US$1.884 billion (definitive agreement terminated) Schultze Special Purpose Acquisition Corp. in its definitive agreement to combine with Clever Leaves, a pharmaceutical-grade multi-national cannabis operator, and its anticipated NASDAQ listing and enterprise value of $255 million Fiorello Pharmaceuticals, Inc, one of ten companies approved to operate a medical cannabis company in the State of New York, in its $60 million acquisition via reverse subsidiary merger by Green Thumb Industries Concord Acquisition Corp in connection with the execution of a definitive business combination agreement with Circle Internet Financial Limited, a global financial technology firm that provides payments and treasury infrastructure for internet businesses and also the principal operator of blockchain-based USD Coin (USDC)(closing pending) Arrival Group, an EV manufacturer, in its definitive agreement to combine with CIIG Merger Corp. and its anticipated NASDAQ listing and enterprise value of $5.4 billion Replay Acquisition Corp. in its definitive agreement to combine with Finance of America Companies, a consumer lending and services platform, and its anticipated NYSE listing and enterprise value of $1.9 billion AstraZeneca PLC in its sale of certain anti-biotics products to an affiliate of Pfizer Inc. for up to $1.575 billion
Skills
- Private Equity
- Venture Capital
- Mergers & Acquisitions
- Securities
- Corporate Governance
- Licensing
- Private Placements
- Equities
- Corporate Law
- Acquisitions
- Due Diligence
- Legal Research
- Restructuring
- Bankruptcy
- Litigation
- M&a Experience
- Finance
- Joint Ventures
- Cross-Border Transactions
- Legal Writing
Find verified contacts for anyone on LinkedIn
Unifers gives sales teams verified emails and direct dials, enriched profiles, and outreach that lands in the inbox.
Free plan included · No credit card required
This profile is compiled from publicly available professional sources. Unifers is not affiliated with or endorsed by LinkedIn. Request removal of this profile.